2011ACCF/AHA美國心血管藥物替換策略聲明
《2011ACCF/AHA美國心血管藥物替換策略聲明》內容簡(jiǎn)介：
This document is an American College of Cardiology Foun-dation （ACCF） health policy statement and is intended topromote or advocate a position, be ***rmational in nature,and offer guidance to the stakeholder community regardingthe ACCF's stance on healthcare policies and programs.Health policy statements are not intended to offer clinicalguidance and do not contradict existing ACCF clinical policy.
《2011ACCF/AHA美國心血管藥物替換策略聲明》內容預覽：
Therapeutic interchange/substitution has been de fined as thedispensation of drugs alternative to those that have been specifically prescribed. These alternative drugs may be eithergeneric drugs or drugs that are similar, albeit not identical.These drugs may also be chemically different with differentpharmacokinetic properties but which are believed to betherapeutically similar.
The concepts of therapeutic interchange and substitutionhave received increasing attention. One of the most commonreasons is the development of multiple drugs in a similarclass, for example, angiotensin-converting enzyme （ACE）inhibitors, beta-blockers, diuretics, statins, or calcium chan-nel blockers. A second group of common reasons is thedevelopment of slightly differing drugs within the same class.Perhaps the most important driving issues are economic. Ashealthcare costs rise inexorably and the limits of patentprotections are either exceeded, circumvented, or ignoredworldwide, generic drugs and devices are often developedand marketed under the understanding that they provide thesame benefit and safety but with greatly reduced costs. Theseissues are all central to the concepts of therapeutic inter-change and substitution and are the focus of this health policystatement.
點(diǎn)擊下載***：《2011ACCF/AHA美國心血管藥物替換策略聲明》
本站所注明來(lái)源為"愛(ài)愛(ài)醫"的文章，版權歸作者與本站共同所有，非經(jīng)授權不得轉載。
本站所有轉載文章系出于傳遞更多信息之目的，且明確注明來(lái)源和作者，不希望被轉載的媒體或個(gè)人可與我們
聯(lián)系zlzs@120.net，我們將立即進(jìn)行刪除處理
